Research study Program year 2024 Source: CMS Open Payments

CatC inhibitor Phase II in bronchiectasis

Research payments

$2,906,071

110 payments

Through program year 2024, $2,906,071 in research payments was reported against CatC inhibitor Phase II in bronchiectasis, across 110 payments.

Paid by (largest first)
Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG; Boehringer Ingelheim International GmbH
ClinicalTrials.gov
No trial number was reported for this study

By program year

3 rows
Year Kind Amount Payments
2024 Research $1,321,259 39
2023 Research $1,172,989 36
2022 Research $411,823 35

Breakdown

Who paid Research payments · program years 2022–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $2,302,137 61 payments
  2. Boehringer Ingelheim Pharma GmbH & Co.KG $385,809 42 payments
  3. Boehringer Ingelheim International GmbH $218,125 7 payments
Who received the money Research payments · program years 2022–2024
  1. Ut Health Center At Tyler Teaching hospital · TX $539,842 3 payments
  2. Metroplex Pulmonary And Sleep Center Organisation paid for research $492,468 7 payments
  3. Newportnativemd INC Organisation paid for research $261,126 8 payments
  4. Uc Davis Medical Center Teaching hospital · CA $199,189 1 payment
  5. NYU School Of Medicine Office Organisation paid for research $182,861 2 payments
  6. Medical University of South Carolina Organisation paid for research $144,787 2 payments
  7. University of Florida Organisation paid for research $133,524 5 payments
  8. Weill Medical College Of Cornell University Organisation paid for research $117,805 7 payments
  9. Georgetown University Organisation paid for research $58,453 5 payments
  10. Robert Wise Pulmonary Disease · Baltimore, MD $51,500 1 payment

Usually the institution or organisation running the study, not a person.

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

9 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record